Masaki Katayama

2.1k total citations
47 papers, 1.1k citations indexed

About

Masaki Katayama is a scholar working on Rheumatology, Molecular Biology and Oncology. According to data from OpenAlex, Masaki Katayama has authored 47 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Rheumatology, 10 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Masaki Katayama's work include Rheumatoid Arthritis Research and Therapies (20 papers), Systemic Lupus Erythematosus Research (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Masaki Katayama is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (20 papers), Systemic Lupus Erythematosus Research (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Masaki Katayama collaborates with scholars based in Japan, United States and Germany. Masaki Katayama's co-authors include Akira Hara, Toshiya Kuno, Kengo Matsunaga, Naoki Yoshimi, 正石橋, Yasuhiro Yamada, Hideki Mori, Hideki Mori, Yoshinobu Hirose and Motomu Hashimoto and has published in prestigious journals such as PLoS ONE, Brain Research and International Journal of Molecular Sciences.

In The Last Decade

Masaki Katayama

45 papers receiving 1.0k citations

Peers

Countries citing papers authored by Masaki Katayama

Since Specialization

Citations

This map shows the geographic impact of Masaki Katayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masaki Katayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masaki Katayama more than expected).

Fields of papers citing papers by Masaki Katayama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masaki Katayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masaki Katayama. The network helps show where Masaki Katayama may publish in the future.

Co-authorship network of co-authors of Masaki Katayama

This figure shows the co-authorship network connecting the top 25 collaborators of Masaki Katayama. A scholar is included among the top collaborators of Masaki Katayama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masaki Katayama. Masaki Katayama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study 2023 ·Lara D. Veeken ·Yoichi Nakayama, Ryu Watanabe, Wataru Yamamoto, Kosuke Ebina, Tôru Hirano, Takuya Kotani, Hideyuki Shiba, Masaki Katayama, Yonsu Son, Hideki Amuro, Akira Ōnishi, Sadao Jinno, Ryota Hara, Kosaku Murakami, Koichi Murata, Hiromu Ito, Masao Tanaka, Shuichi Matsuda, Akio Morinobu, Motomu Hashimoto	5
2	Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis 2023 ·Lara D. Veeken ·Akira Ōnishi, (unknown), Wataru Yamamoto, Ryu Watanabe, Ryota Hara, Masaki Katayama, Yasutaka Okita, Yuichi Maeda, Hideki Amuro, Yonsu Son, (unknown), Kenichiro Hata, Motomu Hashimoto, Jun Saegusa, Akio Morinobu	3
3	Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study 2023 ·International Journal of Molecular Sciences ·Hideyuki Shiba, Takuya Kotani, Koji Nagai, (unknown), Wataru Yamamoto, (unknown), Yumiko Wada, (unknown), (unknown), Yo Ueda, Akira Ōnishi, Koichi Murata, Hideki Amuro, Yonsu Son, Ryota Hara, Tôru Hirano, Kosuke Ebina, Masaki Katayama, Motomu Hashimoto, Tohru Takeuchi	4
4	Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study 2021 ·Clinical Rheumatology ·Kosuke Ebina, Tôru Hirano, Yuichi Maeda, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Akira Ōnishi, Sadao Jinno, Ryota Hara, Yonsu Son, Hideki Amuro, Tohru Takeuchi, (unknown), Masaki Katayama, Keiichi Yamamoto, Makoto Hirao, Yasutaka Okita, Atsushi Kumanogoh, Ken Nakata	16
5	Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study 2021 ·Arthritis Research & Therapy ·Sadao Jinno, Akira Ōnishi, Maureen Dubreuil, Motomu Hashimoto, Wataru Yamamoto, Koichi Murata, Tohru Takeuchi, Takuya Kotani, Yuichi Maeda, Kosuke Ebina, Yonsu Son, Hideki Amuro, Ryota Hara, Masaki Katayama, Jun Saegusa	12
6	Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study 2021 ·Rheumatology International ·Yuichi Maeda, Tôru Hirano, Kosuke Ebina, Ryota Hara, Motomu Hashimoto, Wataru Yamamoto, Kosaku Murakami, Takuya Kotani, Kenichiro Hata, Yonsu Son, Hideki Amuro, Akira Ōnishi, Sadao Jinno, Masaki Katayama, Atsushi Kumanogoh	1
7	THU0174 ANTI-IL-6 RECEPTOR ANTIBODY AMELIORATES DISEASE ACTIVITY OF RHEUMATOID ARTHRITIS PATIENTS WITH KNEE JOINT INVOLVEMENT -ANSWER COHORT STUDY- 2020 ·Annals of the Rheumatic Diseases ·Yuichi Maeda, Tôru Hirano, Ryota Hara, Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Kosaku Murakami, Takuya Kotani, Kenichiro Hata, Yonsu Son, Hideki Amuro, Akira Ōnishi, (unknown), Masaki Katayama, Atsushi Kumanogoh	1
8	Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study- 2020 ·Clinical Rheumatology ·Kosuke Ebina, Tôru Hirano, Yuichi Maeda, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Tohru Takeuchi, Koji Nagai, Yonsu Son, Hideki Amuro, Akira Ōnishi, Sadao Jinno, Ryota Hara, Masaki Katayama, Keiichi Yamamoto, Atsushi Kumanogoh, Makoto Hirao	14
9	Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study 2020 ·Rheumatology International ·Sadao Jinno, Akira Ōnishi, Maureen Dubreuil, Kengo Akashi, Motomu Hashimoto, Wataru Yamamoto, Koichi Murata, Tohru Takeuchi, Takuya Kotani, Yuichi Maeda, Kosuke Ebina, Yonsu Son, Hideki Amuro, Ryota Hara, Masaki Katayama, Jun Saegusa, Akio Morinobu	15
10	The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study 2019 ·Rheumatology International ·Koichi Murata, Motomu Hashimoto, Wataru Yamamoto, Yonsu Son, Hideki Amuro, Koji Nagai, Tohru Takeuchi, Masaki Katayama, Yuichi Maeda, Kosuke Ebina, Ryota Hara, Sadao Jinno, Akira Ōnishi, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Tsuneyo Mimori, Shuichi Matsuda	6
11	Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study 2019 ·Arthritis Research & Therapy ·Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Tôru Hirano, Ryota Hara, Masaki Katayama, Akira Ōnishi, Koji Nagai, Yonsu Son, Hideki Amuro, Keiichi Yamamoto, Yuichi Maeda, Koichi Murata, Sadao Jinno, Tohru Takeuchi, Makoto Hirao, Atsushi Kumanogoh, Hideki Yoshikawa	39
12	Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital 2019 ·Arthritis Research & Therapy ·Wataru Fukuda, Tadamasa Hanyu, Masaki Katayama, (unknown), Akitomo Okada, Masayuki Miyata, (unknown), Masatoshi Hayashi, Yoshinobu Koyama, Kaoru Arii, Toshiyuki Kitaori, Hiroyuki Hagiyama, (unknown), Takahito Yamasaki, (unknown), Takeshi Suzuki, Atsushi Omoto, (unknown), Satoshi Morita, Shigeko Inokuma	15
13	Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study 2018 ·Arthritis Research & Therapy ·Motomu Hashimoto, Moritoshi Furu, (unknown), (unknown), Ryota Hara, Masaki Katayama, Akira Ohnishi, Kengo Akashi, Shuzo Yoshida, Koji Nagai, Yonsu Son, Hideki Amuro, Tôru Hirano, Kosuke Ebina, Ryuji Uozumi, Hiromu Ito, Masao Tanaka, Koichiro Ohmura, Takao Fujii, Tsuneyo Mimori	21
14	Suppressor of TCR signaling-2 (STS-2) suppresses arthritis development in mice 2017 ·Modern Rheumatology ·(unknown), Koichiro Ohmura, Masaki Katayama, Shuji Akizuki, Nick Carpino, Kosaku Murakami, Ran Nakashima, Motomu Hashimoto, Yoshitaka Imura, Hajime Yoshifuji, Masao Tanaka, Tsuneyo Mimori	10
15	Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan 2016 ·Annals of the Rheumatic Diseases ·Wataru Fukuda, Tadamasa Hanyu, Masaki Katayama, (unknown), Akitomo Okada, Masayuki Miyata, (unknown), Masatoshi Hayashi, Yoshinobu Koyama, Kaoru Arii, Toshiyuki Kitaori, Hiroyuki Hagiyama, (unknown), Takahito Yamasaki, (unknown), Tsuyoshi Suzuki, Atsushi Omoto, (unknown), Satoshi Morita, Shigeko Inokuma	64
16	A case of a small pancreatic carcinoma with endocrine tumors 2011 ·Suizo ·Takashi Seino, Tadahisa Inoue, (unknown), Kunihiro Kawabata, Hideki Ishikawa, Masaki Katayama	0
17	Myelin Basic Protein as a Novel Genetic Risk Factor in Rheumatoid Arthritis—A Genome-Wide Study Combined with Immunological Analyses 2011 ·PLoS ONE ·Chikashi Terao, Koichiro Ohmura, Masaki Katayama, Meiko Takahashi, (unknown), Gora Diop, Yoshinobu Toda, (unknown), (unknown), Reiko Shinkura, Masakazu Shimizu, Marta Gut, Simon Heath, Inga Melchers, (unknown), Mark Lathrop, Tsuneyo Mimori, Ryo Yamada, Fumihiko Matsuda	24
18	Chemopreventive Effects of a Flavonoid Antioxidant Silymarin on N‐Butyl‐N‐(4‐ hydroxybutyl)nitrosamine‐induced Urinary Bladder Carcinogenesis in Male ICR Mice 2002 ·Japanese Journal of Cancer Research ·(unknown), Shigeyuki Sugie, Takuji Tanaka, Akira Hara, Yasuhiro Yamada, Masaki Katayama, Takashi Deguchi, Hideki Mori	45
19	Induction of Apoptosis by Sulindac in Azoxymethane‐induced Possible Colonic Premalignant Lesions in Rats 2002 ·Japanese Journal of Cancer Research ·Toshiya Kuno, Yasuhiro Yamada, Yoshinobu Hirose, Masaki Katayama, Keiko Sakata, Akira Hara, Shigetoyo Saji, Hideki Mori	11
20	Suppression of Occurrence and Advancement of β‐Catenin‐accumulated Crypts, Possible Premalignant Lesions of Colon Cancer, by Selective Cyclooxygenase‐2 Inhibitor, Celecoxib 2001 ·Japanese Journal of Cancer Research ·Yasuhiro Yamada, Naoki Yoshimi, Yoshinobu Hirose, Akira Hara, Masahito Shimizu, Toshiya Kuno, Masaki Katayama, 正石橋, Hideki Mori	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact